Iridocorneal Endothelial Syndrome

ROSEMONT, Ill., June 18, 2024 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) announced the recipients of the 2024 MORE Awards. Presented annually to U.S.-based journalists, the MORE Awards acknowledge accurate reporting of musculoskeletal health news topics and celebrate the role media play in accurately educating and informing patients about musculoskeletal health issues, innovative bone and joint treatments, preventative care and patient recovery. "Musculoskeletal conditions are the number one cause of adult disability, and the AAOS MORE Award recipients are journalists who deliver accurate news and information to help educate and serve this population," said AAOS Communications Committee Chair Jason L. Koh, MD, MBA, FAAOS. Entries were judged by a panel of orthopaedic surgeons and evaluated for overall quality and medical accuracy. The winners of the 2024 awards include health and medical writers, photographers and freelance reporters from print, broadcast and online media outlets. From endearing patient stories to perspectives on orthopaedic innovations and treatment options, the award recipients covered an array of bone and joint-health topics. The 2024 MORE Award winners by category are: Newspaper/Magazine Feature Ed Stannard, The Hartford Courant "A CT woman is walking on a 3D-printed ankle. Here's why the surgeon took 'a little bit of a long shot'" Broadcast and Multimedia Feature Sloane Wick, WSAW-TV (Wausau, Wisc.) "Ice-related falls and how you can prevent them this winter" Online Journalism Alexandra Emanuelli, Huffington Post "4 foods and ingredients that have a negative impact on bone density" Mandi Harenberg, HealthDay "When your child has scoliosis: symptoms & treatments" Caroline Hopkins, NBC News "What running does to the knees, according to a large survey of marathon runners" Denise Mann, HealthDay "Which high school sports cause kids the most injuries?" For more information and entry guidelines, visit newsroom.aaos.org. About the AAOS With more than 39,000 members, the American Academy of Orthopaedic Surgeons is the world's largest medical association of musculoskeletal specialists. The AAOS is the trusted leader in advancing musculoskeletal health. It provides the highest quality, most comprehensive education to help orthopaedic surgeons and allied health professionals at every career level to best treat patients in their daily practices. The AAOS is the source for information on bone and joint conditions, treatments and related musculoskeletal health care issues; and it leads the health care discussion on advancing quality. Follow the AAOS on Facebook, X, LinkedIn and Instagram. SOURCE American Academy of Orthopaedic Surgeons

Los Angeles, USA , June 02, 2021 (GLOBE NEWSWIRE) -- Current Therapies and Emerging Drugs in the Prediabetes Pipeline Soon to Boost the Treatment Outlook Prominent companies such as Valbiotis, Resverlogix, Caelus Health, SciMar, Boston Therapeutics, MicroBiome Therapeutics, and others are developing potential drug candidates to boost the Prediabetes treatment scenario. Out of all the emerging therapies, the late-stage product TOTUM-63 (VALBIOTIS) has shown promising results and will significantly impact the Prediabetes treatment market. DelveInsight’s “Prediabetes Pipeline Insight” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the pipeline landscapes. It comprises Prediabetes pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Prediabetes therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Prediabetes pipeline products. Some of the key takeaways from the Prediabetes Pipeline Report Get an overview of pipeline landscape @ Prediabetes Clinical Trials Analysis Prediabetes is a metabolic disorder that is considered a precursor for the development of diabetes mellitus. It is characterised by higher than normal blood glucose levels that have not yet reached diabetic levels. Prediabetes Emerging Drugs TOTUM-63 is a unique and patented combination of 5 plant extracts designed to reduce the risk of developing T2D on prediabetic subjects. TOTUM-63 was developed to challenge perceptions of prediabetes management and help protect the health of prediabetic patients. TOTUM-63 is currently in Phase II/III clinical development program for the Prediabetes treatment. Research and DevelopmentPhase II/IIINCT02868177: In October 2016, Valbiotis initiated a trial, “Totum-63 Effect on Glucose and Lipid Homeostasis in People With Abdominal Obesity Associated With Impaired Glucose Tolerance or Untreated Type 2 Diabetes and Hypertriglyceridemia”. The primary objective of the study was to assess the beneficial effect of Totum-63 compared to a placebo on glucose homeostasis assessed by the fasting plasma glucose level in prediabetics or untreated type 2 diabetics after 24 weeks of consumption. The study got completed in April 2019. Results:In July 2019, VALBIOTIS announced positive results (topline data) for the Phase IIA study of VALEDIA (active substance: TOTUM-63), which evaluated this product’s efficacy in a prediabetic population, compared to placebo. Eubacterium hallii is a microbiota-based dietary supplement currently under clinical intervention in subjects suffering from metabolic syndrome/prediabetes. The product is in Phase II clinical development for the treatment of Prediabetes. Research and DevelopmentNCT04529473: In August 2020, Caelus Health initiated a trial titled “A Double-blind, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Markers of Glycaemic Control in Healthy Hyperglycaemic Males”. This study aims to evaluate the effect of administration of a next-generation probiotic, Eubacterium hallii, versus placebo on insulin sensitivity and glycemic control, in volunteers with some markers of metabolic syndrome. The trial is currently recruiting with an estimated enrollment of 100 participants and is expected to be completed in January 2022. For further information, refer to the detailed report @ Prediabetes Pipeline Therapeutics Scope of Prediabetes Pipeline Drug Insight Key Questions regarding Current Prediabetes Treatment Landscape and Emerging Therapies Answered in the Pipeline Report Table of Contents Get a customised pipeline report @ Prediabetes Drugs Pipeline Report Related Reports DelveInsight's Prediabetes - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Prediabetes - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Prediabetes in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. DelveInsight's "Multiple Organ Dysfunction Syndrome Market Report 2030" delivers an in-depth understanding, historical and forecasted epidemiology, market trends in the 7MM. DelveInsight's Corneal Endothelial Dystrophy - Market Insights, Epidemiology and Market Forecast - 2030 report provides detailed insights on historical and forecasted epidemiology. DelveInsight's Onychomycosis - Market Insights, Epidemiology and Market Forecast - 2030 report provides an overview and an understanding of historical and forecasted epidemiology. DelveInsight's Deep Vein Thrombosis Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology in 7MM. About DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.

Dublin, April 06, 2021 (GLOBE NEWSWIRE) -- The "Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of Corneal Endothelial Dystrophy (CED), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.Scope of the Report Report Highlights Report Insights Report Key Strengths Key QuestionsMarket Insights: Current Treatment Scenario, Marketed Drugs, and Emerging Therapies: Companies Mentioned For more information about this drug pipelines report visit About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.